Antidepressant Therapy's Impact on Vascular Function in Post-Preeclampsia Women
This early phase study aims to evaluate the impact of antidepressant therapy on vascular function, specifically microvascular and nitric oxide-dependent dilation responses, in women who have previously experienced preeclampsia.
Paroxetine Hydrochloride
+ Ascorbic acid (Vitamin C)
Urogenital Diseases+2
+ Female Urogenital Diseases and Pregnancy Complications
+ Pregnancy Complications
Basic Science Study
Summary
Study start date: August 30, 2026
Actual date on which the first participant was enrolled.Preeclampsia is a condition where a pregnant woman experiences high blood pressure and other complications. Women who have had preeclampsia are more likely to develop heart disease and depression later in life. This might be due to damage to their blood vessels during pregnancy. This study aims to understand how preeclampsia and depression are linked to changes in blood vessel health. It also explores if treating depression can improve blood vessel health in women who've had preeclampsia, potentially reducing their risk of heart disease. The study compares blood vessel function in women who've had preeclampsia with those who haven't, and in women with and without depression. It uses a technique called laser-Doppler flowmetry to measure how well blood vessels respond to different treatments. This involves heating the skin and observing blood flow changes. The study also looks at how a drug used to treat depression, called L-NAME, affects blood vessel function. The primary outcomes of the study are the responses of blood vessels to local heating and to L-NAME.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.40 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Basic Science Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Female
Biological sex of participants that are eligible to enroll.From 18 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: 18-24 years old, 12 weeks - 5 years post pregnancy one of the following: 1. a history of a normal pregnancy with a current diagnosis of depression, 2. a history of a normal pregnancy without a current diagnosis of depression, 3. a history of a preeclamptic pregnancy with a current diagnosis of depression, 4) and history of preeclamptic pregnancy without a current diagnosis of depression. Exclusion Criteria: history of cardiovascular, metabolic, and/or skin diseases current or history of tobacco/nicotine/ e-cigarette use history of gestational diabetes current antihypertensive or cholesterol-lowering medication currently pregnant allergy to materials used during the experiment (e.g. latex), known allergy to study drugs currently using SSRI medications
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location